Insiders Trades
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (13 ops.)
Latest filing published 15 Sept 2026 for Neurocrine Biosciences INC. Read the official filing
Filing timeline
BuySaleKevin Charles Gorman
Insider track record
Disclosed buys
1
Disclosed sells
13
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Kevin Charles Gorman: trading record in brief
Kevin Charles Gorman has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Neurocrine Biosciences Inc and Xencor Inc. In total, 30 filings cover trades dated from 11 January 2016 to 11 September 2026.
Both buying and selling appear: 1 purchase worth €941, against 13 sales worth €36.4M. The amount is not disclosed for 3 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 6 share grants and 10 option exercises. In 2026 alone, the filings show no purchases and 1 sale.
The record was last updated on 15 September 2026 with a share grant (€1.1M) in Neurocrine Biosciences Inc. The latest purchase dates back some time: it was published 976 days ago, on 15 February 2024. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Kevin Charles Gorman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations30 total
14,343 shares0Common StockSEC:0001201096-26-000018:0
7,839 shares@ US$156.22Common StockSEC:0001201096-26-000018:1
10,302 shares0Common StockSEC:0001201096-26-000016:0
205,088 shares@ US$43.240.048% mcap15.4% of flowCommon StockSEC:0001201096-26-000010:0
245,088 shares@ US$154.33180.20% mcap65.5% of flowCommon StockSEC:0001201096-26-000010:1
5,604 shares0Common StockSEC:0001201096-26-000005:0
5,142 shares0Common StockSEC:0001201096-26-000003:0
106,322 shares@ US$35.996.2% of flowCommon StockSEC:0000914475-25-000166:0
13,686 shares0Common StockSEC:0001127602-25-017597:0
9,613 shares@ US$120.37981.9% of flowCommon StockSEC:0000914475-25-000137:0
5,376 shares0Common StockSEC:0000914475-25-000073:0
4,318 shares0Common StockSEC:0000914475-25-000052:0
5,141 shares0Common StockSEC:0000914475-25-000031:0
146,105 shares@ US$32.999.3% of flowCommon StockSEC:0000914475-25-000009:0
2,654 shares@ US$20.6898.1% of flowCommon StockSEC:0001127602-24-024672:0
5,986 shares0Common StockSEC:0001127602-24-018831:0
53 shares@ US$19.121.9% of flowCommon StockSEC:0001127602-24-005195:0
Canonical exit: 13 May 2024 (T+90)
2,832 shares@ US$133.01570.7% of flowCommon StockSEC:0000914475-24-000073:0
2,778 shares@ US$35.990.2% of flowCommon StockSEC:0000914475-24-000056:0
3,040 shares@ US$142.17710.8% of flowCommon StockSEC:0000914475-24-000046:0
2,707 shares@ US$140.68880.7% of flowCommon StockSEC:0000914475-24-000028:0
105,835 shares@ US$19.593.8% of flowCommon StockSEC:0000914475-24-000009:0
9,328 shares@ US$107.39881.8% of flowCommon StockSEC:0001209191-23-047137:0
5,007 shares0Common StockSEC:0001127602-23-019287:0
3,040 shares@ US$105.67720.6% of flowCommon StockSEC:0001209191-23-007912:0
25 of 30 declarations
